Circulating immune cell and microRNA in patients with uveal melanoma developing metastatic disease.

PubWeight™: 1.02‹?› | Rank: Top 15%

🔗 View Article (PMC 4143188)

Published in Mol Immunol on December 25, 2013

Authors

Susan Achberger1, Wayne Aldrich1, Raymond Tubbs2, John W Crabb3, Arun D Singh3, Pierre L Triozzi4

Author Affiliations

1: Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, United States.
2: Department of Molecular Pathology, Cleveland Clinic Foundation, Cleveland, OH, United States.
3: Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, OH, United States.
4: Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, United States. Electronic address: triozzp@ccf.org.

Articles citing this

Regulation of tumor metastasis by myeloid-derived suppressor cells. Annu Rev Med (2014) 1.29

MicroRNA dysregulation in uveal melanoma: a new player enters the game. Oncotarget (2015) 1.11

Regulation of cancer metastasis by cell-free miRNAs. Biochim Biophys Acta (2014) 1.02

Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell Melanoma Res (2014) 0.99

Comparison of a healthy miRNome with melanoma patient miRNomes: are microRNAs suitable serum biomarkers for cancer? Oncotarget (2015) 0.95

Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy. Cancer Immunol Immunother (2014) 0.94

MicroRNA-365 inhibits growth, invasion and metastasis of malignant melanoma by targeting NRP1 expression. Int J Clin Exp Pathol (2015) 0.85

miRNA profiling in vitreous humor, vitreal exosomes and serum from uveal melanoma patients: Pathological and diagnostic implications. Cancer Biol Ther (2015) 0.84

MiR-223-3p targeting SEPT6 promotes the biological behavior of prostate cancer. Sci Rep (2014) 0.84

Circulating miR-21, miR-378, and miR-940 increase in response to an acute exhaustive exercise in chronic heart failure patients. Oncotarget (2016) 0.83

Assay reproducibility in clinical studies of plasma miRNA. PLoS One (2015) 0.79

A restricted signature of serum miRNAs distinguishes glioblastoma from lower grade gliomas. J Exp Clin Cancer Res (2016) 0.79

microRNA-20a in human faeces as a non-invasive biomarker for colorectal cancer. Oncotarget (2016) 0.78

Orchestrating epigenetic roles targeting ocular tumors. Onco Targets Ther (2016) 0.77

MicroRNA-155-IFN-γ Feedback Loop in CD4(+)T Cells of Erosive type Oral Lichen Planus. Sci Rep (2015) 0.75

Oncogenic role of microRNA‑20a in human uveal melanoma. Mol Med Rep (2016) 0.75

MicroRNA profiling of patient plasma for clinical trials using bioinformatics and biostatistical approaches. Onco Targets Ther (2016) 0.75

Expression of natural killer cell regulatory microRNA by uveal melanoma cancer stem cells. Clin Exp Metastasis (2016) 0.75

The biology of uveal melanoma. Cancer Metastasis Rev (2017) 0.75

Surgery-induced monocytic myeloid-derived suppressor cells expand regulatory T cells in lung cancer. Oncotarget (2017) 0.75

miR-196b, miR-378a and miR-486 are predictive biomarkers for the efficacy of vaccine treatment in colorectal cancer. Oncol Lett (2017) 0.75

Articles cited by this

Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A (2008) 33.65

miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell (2007) 9.08

Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology (2011) 3.52

Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J Clin Invest (2010) 3.41

Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery. Immunity (2008) 2.78

MicroRNA-21 and microRNA-148a contribute to DNA hypomethylation in lupus CD4+ T cells by directly and indirectly targeting DNA methyltransferase 1. J Immunol (2010) 2.63

Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci (2003) 2.58

Cutting edge: the Foxp3 target miR-155 contributes to the development of regulatory T cells. J Immunol (2009) 2.51

Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma. Clin Cancer Res (2012) 2.25

microRNAs and the immune response. Curr Opin Pharmacol (2009) 2.18

The microRNA miR-181 is a critical cellular metabolic rheostat essential for NKT cell ontogenesis and lymphocyte development and homeostasis. Immunity (2013) 2.13

Micromarkers: miRNAs in cancer diagnosis and prognosis. Expert Rev Mol Diagn (2010) 2.00

The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy. Cancer Res (2011) 1.56

Reprogramming tumor-associated dendritic cells in vivo using miRNA mimetics triggers protective immunity against ovarian cancer. Cancer Res (2012) 1.51

Transcriptome analysis shows activation of circulating CD8+ T cells in patients with severe asthma. J Allergy Clin Immunol (2011) 1.35

Enrichment of human CD4+ V(alpha)24/Vbeta11 invariant NKT cells in intrahepatic malignant tumors. J Immunol (2009) 1.25

In aged mice, outgrowth of intraocular melanoma depends on proangiogenic M2-type macrophages. J Immunol (2010) 1.15

miR-223 suppresses differentiation of tumor-induced CD11b⁺ Gr1⁺ myeloid-derived suppressor cells from bone marrow cells. Int J Cancer (2011) 1.08

Dysregulated microRNAs affect pathways and targets of biologic relevance in nasal-type natural killer/T-cell lymphoma. Blood (2011) 1.08

microRNA-342, microRNA-191 and microRNA-510 are differentially expressed in T regulatory cells of type 1 diabetic patients. Cell Immunol (2010) 1.07

Immune escape mechanisms of intraocular tumors. Prog Retin Eye Res (2009) 1.07

Intratumoral forkhead box P3-positive regulatory T cells predict poor survival in cyclooxygenase-2-positive uveal melanoma. Cancer (2010) 0.98

Circumventing immune tolerance through epigenetic modification. Curr Pharm Des (2010) 0.97

Human leukocyte antigen class I expression. Marker of poor prognosis in uveal melanoma. Invest Ophthalmol Vis Sci (1997) 0.97

The therapeutic potential of microRNA modulation. Discov Med (2010) 0.97

Tumor infiltrating lymphocytes in uveal melanoma: a link with clinical behavior? Int J Immunopathol Pharmacol (2006) 0.95

MicroRNA regulation of T-cell development. Immunol Rev (2013) 0.93

miR-15a and 16-1 are downregulated in CD4+ T cells of multiple sclerosis relapsing patients. Int J Neurosci (2012) 0.89

Activated CD11b+ CD15+ granulocytes increase in the blood of patients with uveal melanoma. Invest Ophthalmol Vis Sci (2009) 0.89

NKT cell exacerbation of liver metastases arising from melanomas transplanted into either the eyes or spleens of mice. Invest Ophthalmol Vis Sci (2011) 0.88

Natural killer cell regulation by microRNAs in health and disease. J Biomed Biotechnol (2012) 0.87

Chromosome 3 status in uveal melanoma: a comparison of fluorescence in situ hybridization and single-nucleotide polymorphism array. Invest Ophthalmol Vis Sci (2012) 0.85

Neoadjuvant interferon alfa-2b treatment in a murine model for metastatic ocular melanoma: a preliminary study. Arch Ophthalmol (2000) 0.84

Circulating tumor cells in uveal melanoma. Future Oncol (2011) 0.83

Evidence for natural killer cell-mediated protection from metastasis formation in uveal melanoma patients. Invest Ophthalmol Vis Sci (2009) 0.82

Invariant NKT cell development and function in microRNA-223 knockout mice. Int Immunopharmacol (2010) 0.78

Alterations of lymphocyte subpopulations in choroidal melanoma patients undergoing surgery. Rocz Akad Med Bialymst (2005) 0.78

Elevated blood β-2 microglobulin is associated with tumor monosomy-3 in patients with primary uveal melanoma. Melanoma Res (2013) 0.77

Flow cytometry analysis of peripheral blood lymphocytes in patients with choroidal melanoma. Am J Ophthalmol (1997) 0.77